Objective: HIV controllers demonstrate high rates of spontaneous clearance of hepatitis C virus (HCV) infection. The objective of this study was to evaluate the role of human leukocyte antigen (HLA) B Ã 57 and other genetic polymorphisms on HCV clearance in HIV controllers.
below the detection limits of commercially available assays, and second, viremic controllers, who have measurable, but very low levels of HIV RNA (< 2000 copies/ml). HIV controllers represent 'outliers' in the clinical HIV spectrum, and are considered very important for studies of host immunological and genetic factors that control viral replication, with the expectation that they will inform vaccine and drug development, or perhaps identify strategies to achieve a 'functional cure [1,2]'.
Interestingly, HIV controllers may also be more likely to spontaneously clear hepatitis C virus (HCV) infection. While not observed in all studies [3, 4] , most studies suggest a significantly higher rate of spontaneous HCV clearance in HIV controllers (23-39%) [5, 6] than in monoinfected groups (25%) [7] and HIV noncontrollers (6.6-10%) [1, 5] . This has led several groups to examine host genetic factors that might contribute to the control of both virus infections. For example, HLA B Ã 57, the major histocompatibility class I allele, is highly enriched in HIV controllers and is also associated with spontaneous HCV clearance [8] [9] [10] . In contrast, HLA Cw Ã 04 has been associated with faster progression of both HIV disease and chronic HCV infection [11, 12] . The interleukin (IL)28B CC genotype has been shown to be significantly associated with spontaneous control of HCV [13] [14] [15] [16] , conferring a 1.7-3.1 higher odds of clearance than CT and TT genotypes [17] .
Whether the CC genotype of IL28B is also enriched in HIV controllers remains controversial. A relatively small Spanish study found that the CC genotype of IL28B was enriched in white HIV controllers relative to noncontrollers [4] , whereas other studies in primarily AfricanAmerican cohorts have not observed this [6, 18] . Furthermore, none of the much larger genome-wide association studies have found an association between the IL28B CC genotype and HIV control, at least at the genome-wide level of significance [19] [20] [21] [22] . In one study [23] , the IL28B CC genotype has been associated with higher all-cause mortality among all people living with HIV.
In this study, we investigated the degree to which spontaneous clearance of HCV could be explained by HLA B Ã 57 and/or IL28B CC genotype in a well characterized cohort of HIV controllers. HIV-infected adults were sampled from the Study of the Consequences of the Protease Inhibitor Era (SCOPE), a clinic-based cohort of more than 1600 HIV-infected individuals at the University of California, San Francisco. This observational study of HIV-1 infected individuals has a large data and specimen bank of samples with carefully characterized clinical data, including HLA typing, and includes a large sample of HIV controllers [24] . For this study, we included only anti-HCV positive participants, identified using a third-generation enzyme immunoassay (EIA3) (Ortho Clinical Diagnostics, Rochester, New York, USA). Participants were classified as 'HIV controllers' if they were elite controllers or viremic controllers. 'Noncontrollers' had at least one HIV viral load (>10 000 copies/ml) as measured by bDNA (Quantiplex HIV RNA, version 3.0; Chiron Corporation, Emeryville, California, USA) prior to or during ART.
AIDS
HCV RNA was measured using discriminatory HCV transcription mediated amplification (dTMA) assay component of the Procleix HIV-1/HCVassay, developed and manufactured by Gen-Probe (San Diego, California, USA) and marketed by Novartis Vaccines and Diagnostics, New York, New York, USA. The 50% limit of detection of this assay is 12.1 copies/ml [95% confidence interval (CI), 11.1-13.2] of HCV RNA when using the recommended 0.5-ml plasma input volume. Participants were classified as having spontaneously cleared HCV infection if they had detectable anti-HCV but no detectable HCV RNA and had no history of HCV treatment. To evaluate whether any of the known host genetic determinants of HCV clearance were enriched in HIV controllers, we compared the genetic polymorphisms known to be associated with control of HIV and HCV in the HIV controller group with the HIV noncontrollers.
Genetic testing for IL28B SNP polymorphism was conducted using real-time PCR amplification. The methodology of determining IL28B SNP polymorphism has been previously reported [25] .
HLA typing was done using PCR sequence specific oligonucleotide probing [26] . Those positive for HBsAg or with a self-reported history of hepatitis treatment were excluded. The study was approved by the Committee for Human Subjects at the University of California San Francisco and all participants gave informed consent before undergoing any study-related procedures.
Statistical analyses
The main outcome variable of this study is spontaneous HCV clearance, as defined above. 
Results
Of the 279 HIV/HCV-coinfected participants included in the analysis, 48 (17%) were HIV controllers. There was no difference in the sex, age or racial distribution between the HIV controller and noncontroller groups (Table 1) . HCV clearance did not appear to differ between HIV controllers and noncontrollers in unadjusted analyses (35 vs. 27%, P ¼ 0.23).
HIV controllers were significantly enriched for HLA B Ã 57 compared with HIV noncontrollers (33 vs. 10%, P < 0.001; Table 2 ). However, the HLA Cw Ã 04 allele was similarly represented in controllers and noncontrollers (26 vs. 17%, P ¼ 0.19), as was the IL28B CC genotype (25 vs. 39%, P ¼ 0.49). The only genetic factor significantly different by HCV clearance status was IL28B CC: 59% of clearers were CC positive compared to 27% of nonclearers (P < 0.001; Table 2 ). We next examined these associations stratified by sex (Table 3) . Male HIV controllers were significantly more likely to have HLA B Ã 57 than male noncontrollers (42 vs. 10%, P < 0.001), but female HIV controllers did not appear to be enriched for HLA B Ã 57. Both women and men who cleared HCV were significantly more likely to be IL28B CC positive than non-HCV clearers. The presence of HLA B Ã 57 was not associated with HCV clearance among men or women.
To further evaluate whether HLA B Ã 57 might explain the increased prevalence of HCV clearance on HIV controllers, we stratified our analysis by HLA B Ã 57 status. Of the 24 HIV noncontrollers positive for HLA B Ã 57, more than half (54%) spontaneously cleared their HCV infection than 36% of the 207 HIV noncontrollers without HLA B Ã 57 (P ¼ 0.09, Table 3 ). However, among HIV controllers, spontaneous HCV clearance rates were high both in those with and without B Ã 57 (54 and 59%, respectively, P ¼ 0.84, P for interaction ¼ 0.01). The results of the multivariable analyses are shown in Table 4 . After adjusting for HLA B Ã 57, sex, age and race, two factors: HIV controller status (APR 1.78 (95% CI 1.06-3.00); P ¼ 0.032) and IL28B CC genotype (APR 2.76 (95% CI 1.85-4.11); P < 0.001), were independently associated with spontaneous HCV clearance.
Discussion
In the current study, we confirm prior studies demonstrating higher rates of spontaneous HCV clearance in HIV controllers [5] [6] [7] . We did not observe crude differences in the proportions of HIV controllers and noncontrollers who cleared HCV, however, in multivariable analyses, HIV controller status was independently predictive of HCV clearance. Results also suggest that HLA B Ã 57, a factor known to be associated with HIV controller status, is not explanatory of this association between controller status and HCV clearance. A recent study [27] has suggested that HLA B Ã 57 might be associated with promoting a more robust HCV-specific T cell response, however, the combined findings that HLA B Ã 57 was not associated with HCV clearance, and the equally high proportion of HIV controllers with (31%) and without (35%) HLAB Ã 57 who cleared HCV suggests that other mechanisms or host factors are at play.
The HLA Cw Ã 04 allele also failed to explain the increased proportion of HCV clearance in HIV controllers. Given the lack of association of IL28B genotype and HIV controller status, these results suggest that other factors associated with HIV controller status and as yet unmeasured in this group are associated with HCV clearance.
As noted, a high proportion of HIV-infected controllers and noncontrollers in this cohort demonstrated a spontaneous HCV clearance. The 27% rate of spontaneously cleared HCV infection among HIV noncontrollers is much higher than normally seen in HIVinfected populations [28] . It is likely that most of these people experienced their HCV infection and subsequent clearance before their HIV infection [29] . Few, if any, were infected with HCV after ART-mediated immune recovery, although HCV reinfection cannot be ruled out [30] .
Women have been shown to be almost three times more likely to clear HCV infection than men [31] . However, we found no difference in HCV clearance rates by sex overall, or stratified by HIV controller status. We also did not observe differences in HCV clearance by sex and IL28B genotype, as others have recently reported [15, 32] . There is little evidence that HCV risk differed by HIV controller group; injection drug use was reported equally.
One study has suggested an association between sexually acquired HCV and HCV clearance [33] , but this association has not been seen prospectively, nor has this been observed in HIV-positive MSM, a group well represented within the SCOPE cohort [34] . There is no clear explanation for why men were equally likely to clear their HCV infection as women in this cohort.
There are some limitations to this study. We excluded those with a history of prior HCV treatment on the basis of self-report. It is possible that there was underreporting of HCV treatment history; Medical record review was undertaken at our institution and failed to identify prior HCV treatment among any patients reporting no history of treatment. However, if mis-classification of treatment did occur, the proportion of those who demonstrated spontaneous clearance would be smaller and the role of the genetic markers in these patients overestimated.
Understanding the shared and separate mechanisms that contribute to the control of HIVand HCV may shed light on future directions for treatment, prevention and vaccine development for both viruses. Because HIV controllers are more likely to clear HCV infection than HIV noncontrollers, this unique group may provide new insights into the mechanisms underlying viral control. Our study suggests that host factors other than HLAB Ã 57, a factor highly associated with controller status, does not contribute to HCV clearance, and that IL28B CC genotype does. Identifying other factors that contribute to enhanced viral control may support the development of novel vaccine and treatment strategies for HIV and HCV, ultimately reducing the morbidity and mortality caused by these viruses. 
